PeptideScanner retained ClinicalTrials.gov record NCT01723774 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT06738979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07035093 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT07842640 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07511543 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-24, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07803744 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07836140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07321886 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT06862908 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT07832799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT06465186 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT05714683 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07829198 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05928390 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT07148960 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT06858839 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07639021 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04756401 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT06810583 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT06045221 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06649045 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06908694 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07816562 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT05536804 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06660173 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07415954 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07811895 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07812597 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07812636 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07746895 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT07770841 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03811561 at 2026-09-09T19:17:17.089Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06926842 at 2026-09-09T19:17:17.080Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT07247084 at 2026-09-09T19:17:17.101Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07662213 at 2026-09-09T19:17:17.121Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03905707 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04881825 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT06973304 at 2026-11-15T21:55:23.600Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05872620 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06439277 at 2026-09-09T19:17:17.406Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06851962 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07803705 at 2026-09-09T19:17:17.113Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT05776472 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT05971940 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07801664 at 2026-09-09T19:17:17.074Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07803250 at 2026-09-09T19:17:17.410Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was bpc-157.
PeptideScanner retained ClinicalTrials.gov record NCT07083154 at 2026-09-09T19:17:17.091Z. Its registry update date was 2026-09-02, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT07797335 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-01, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT06635629 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT07739537 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06513962 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT06709573 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT07795164 at 2026-09-09T19:17:17.076Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was pemvidutide.
PeptideScanner retained ClinicalTrials.gov record NCT03457948 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT03937882 at 2026-11-16T01:44:56.605Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
PeptideScanner retained ClinicalTrials.gov record NCT07765602 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was rusfertide.
PeptideScanner retained ClinicalTrials.gov record NCT07215949 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT06961747 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT07252401 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT07575399 at 2026-09-09T19:17:17.083Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00066690 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-08-26, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT06747468 at 2026-11-16T01:46:44.871Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was avexitide.
PeptideScanner retained ClinicalTrials.gov record NCT07668401 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT06383390 at 2026-09-09T19:17:17.103Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT07596212 at 2026-09-09T19:17:17.112Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03969329 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT04278404 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT07780721 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT05929066 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT07313813 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07738614 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-20, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT05142696 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07214298 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT07426380 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT05747534 at 2026-11-16T01:45:58.486Z. Its registry update date was 2026-08-18, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT05869903 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07765511 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT07150806 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07087795 at 2026-08-13T16:32:13.881Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03883412 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05478707 at 2026-08-13T05:54:14.860Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07046819 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07218354 at 2026-08-13T05:54:14.857Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07734870 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06339411 at 2026-11-16T17:33:14.861Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT04113109 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT06965413 at 2026-08-13T05:52:27.007Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06651177 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06080074 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06632444 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT05509569 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT07264634 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was palopegteriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT06739122 at 2026-08-13T05:52:27.010Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07589686 at 2026-08-13T05:52:27.014Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07455903 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07742735 at 2026-11-16T01:47:19.543Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05663515 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07745504 at 2026-08-13T05:52:27.004Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT03941236 at 2026-11-16T01:42:39.027Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT06139419 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT06217562 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT05724108 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT06993792 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06987513 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was pemvidutide.
PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT05765500 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06305182 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT06972459 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT05796388 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT07706764 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was palopegteriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07719933 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT04484818 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06169124 at 2026-08-13T05:56:16.370Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07191873 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07559500 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07732426 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07729332 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07225829 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06072963 at 2026-08-10T18:10:03.864Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06388642 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT07037433 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07101445 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT07496463 at 2026-08-10T18:10:04.219Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT07723924 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT07587775 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT03796884 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT06164795 at 2026-08-10T18:10:03.919Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07257484 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT04297683 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT06967389 at 2026-08-10T18:10:03.916Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06975111 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07715929 at 2026-08-10T18:10:04.226Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07718126 at 2026-08-10T18:10:03.957Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT05931380 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06378866 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07707778 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06370728 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06440980 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07602699 at 2026-08-10T18:10:03.953Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT02325674 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT06679270 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT07665879 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT06814938 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06817356 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT06596135 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-15, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT06934642 at 2026-08-10T18:10:03.939Z. Its registry update date was 2026-07-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07160179 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT06855758 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT05896293 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04037254 at 2026-11-16T17:31:07.936Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was gonadorelin.
PeptideScanner retained ClinicalTrials.gov record NCT05498272 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07417631 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02319837 at 2026-08-10T18:10:03.933Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06727331 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07693608 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT03671330 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT05616013 at 2026-08-10T18:10:03.915Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06935838 at 2026-08-10T18:10:03.949Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06174779 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.
PeptideScanner retained ClinicalTrials.gov record NCT05569772 at 2026-08-10T18:10:03.935Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06893211 at 2026-08-10T18:10:03.966Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07682818 at 2026-08-10T18:10:03.938Z. Its registry update date was 2026-07-06, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT06745466 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT05371496 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07671248 at 2026-07-30T16:38:53.229Z. Its registry update date was 2026-07-01, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06010004 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07220642 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT07674290 at 2026-07-30T16:19:03.062Z. Its registry update date was 2026-06-29, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT04822181 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04901936 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT04777409 at 2026-07-30T16:19:03.047Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07592546 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07607587 at 2026-07-30T16:19:03.059Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT07505303 at 2026-07-30T16:19:03.067Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07668414 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03070886 at 2026-07-30T16:19:03.056Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06016855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT06230523 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT07158021 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-23, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05046860 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-06-22, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT06024356 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT04423211 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.